Can Urinary Biomarkers Replace Cystoscopy?

Overview

Journal World J Urol

Specialty Urology

Date 2018 Oct 5

PMID 30283995

Citations 24

Authors

Moritz Maas

Jens Bedke

Arnulf Stenzl

Tilman Todenhofer

Affiliations

Soon will be listed here.

Abstract

Purpose: Diagnosis and follow-up in patients with non-muscle invasive bladder cancer (NMIBC) rely on cystoscopy and urine cytology. The aim of this review paper is to give an update on urinary biomarkers and their diagnosis and surveillance potential. Besides FDA-approved markers, recent approaches like DNA methylation assays, mRNA gene expression assays and cell-free DNA (cfDNA) are evaluated to assess whether replacing cystoscopy with urine markers is a potential scenario for the future.

Methods: We performed a non-systematic review of current literature without time period restriction using the National Library of Medicine database ( http://ww.pubmed.gov ). The search included the following key words in different combinations: "urothelial carcinoma", "urinary marker", "hematuria", "cytology" and "bladder cancer". Further, references were extracted from identified articles. The results were evaluated regarding their clinical relevance and study quality.

Results: Currently, replacing cystoscopy with available urine markers is not recommended by international guidelines. For FDA-approved markers, prospective randomized trials are lacking. Newer approaches focusing on molecular, genomic and transcriptomic aberrations are promising with good accuracies. Furthermore, these assays may provide additional molecular information to guide individualized surveillance strategies and therapy. Currently ongoing prospective trials will determine if cystoscopy reduction is feasible.

Conclusion: Urinary markers represent a non-invasive approach for molecular characterization of the disease. Although fully replacing cystoscopy seems unrealistic in the near future, enhancing the current gold standard by additional molecular information is feasible. A reliable classification and differentiation between aggressive and nonaggressive tumors by applying DNA, mRNA, and cfDNA assays may change surveillance to help reduce cystoscopies.

Citing Articles

Music from Noise-Canceling Headphones Is Beneficial against Anxiety in Male Bladder Cancer Patients Undergoing Follow-Up Cystoscopy: A Prospective Randomized Trial.

Cho H, Chung H, Hwang E, Jung S, Kwon D, Park K Urol Int. 2024; 108(5):414-420.

PMID: 38735280 PMC: 11449191. DOI: 10.1159/000539312.

Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer.

Wang X, Song D, Zhu B, Jin Y, Cai C, Wang Z Anticancer Drugs. 2024; 35(4):362-370.

PMID: 38385960 PMC: 10919263. DOI: 10.1097/CAD.0000000000001571.

Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.

Feng Y, Huo Q, Li B, Yokota H Proteomes. 2024; 12(1).

PMID: 38250812 PMC: 10801584. DOI: 10.3390/proteomes12010001.

Novel urine-based DNA methylation biomarkers for urothelial bladder carcinoma detection in patients with hematuria.

Abol-Elnazer H, Awadalla A, Ahmed A, Abol-Enein H, Al Ganzouri M, Elsawy A Arab J Urol. 2024; 21(4):248-257.

PMID: 38178946 PMC: 10763582. DOI: 10.1080/2090598X.2023.2208492.

Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.

Mengual L, Frantzi M, Mokou M, Ingelmo-Torres M, Vlaming M, Merseburger A Br J Cancer. 2022; 127(11):2043-2051.

PMID: 36192490 PMC: 9681771. DOI: 10.1038/s41416-022-01992-3.

References

Konety B, Nguyen T, Dhir R, Day R, Becich M, Stadler W . Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000; 6(7):2618-25. View

Lokeshwar V, Schroeder G, Selzer M, Hautmann S, Posey J, Duncan R . Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 2002; 95(1):61-72. DOI: 10.1002/cncr.10652. View

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View

Shariat S, Casella R, Khoddami S, Hernandez G, Sulser T, Gasser T . Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004; 171(2 Pt 1):626-30. DOI: 10.1097/01.ju.0000107826.78479.90. View

Svatek R, Herman M, Lotan Y, Casella R, Hsieh J, Sagalowsky A . Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer. 2006; 106(8):1701-7. DOI: 10.1002/cncr.21795. View

Savic S, Zlobec I, Thalmann G, Engeler D, Schmauss M, Lehmann K . The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer. 2009; 124(12):2899-904. DOI: 10.1002/ijc.24258. View

van der Aa M, Steyerberg E, Bangma C, van Rhijn B, Zwarthoff E, van der Kwast T . Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol. 2009; 183(1):76-80. DOI: 10.1016/j.juro.2009.08.150. View

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T . Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010; 14(4):1-331, iii-iv. DOI: 10.3310/hta14040. View

Mengual L, Burset M, Ribal M, Ars E, Marin-Aguilera M, Fernandez M . Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010; 16(9):2624-33. DOI: 10.1158/1078-0432.CCR-09-3373. View

10.

Brems-Eskildsen A, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F . Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer. 2010; 10:646. PMC: 3001447. DOI: 10.1186/1471-2407-10-646. View

11.

Moatamed N, Apple S, Bennett C, Aronson W, Klisak I, Shirley B . Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay. Diagn Cytopathol. 2011; 41(3):218-25. DOI: 10.1002/dc.21831. View

12.

Kamat A, Dickstein R, Messetti F, Anderson R, Pretzsch S, Gonzalez G . Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012; 187(3):862-7. PMC: 3278506. DOI: 10.1016/j.juro.2011.10.144. View

13.

Todenhofer T, Hennenlotter J, Kuhs U, Tews V, Gakis G, Aufderklamm S . Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology. 2012; 79(3):620-4. DOI: 10.1016/j.urology.2011.10.067. View

14.

Aly M, Khaled H, Emara M, Hussein T . Cytogenetic profile of locally advanced and metastatic Schistosoma-related bladder cancer and response to chemotherapy. Cancer Genet. 2012; 205(4):156-62. DOI: 10.1016/j.cancergen.2012.01.011. View

15.

OSullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L . A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012; 188(3):741-7. DOI: 10.1016/j.juro.2012.05.003. View

16.

Todenhofer T, Hennenlotter J, Aufderklamm S, Kuhs U, Gakis G, Germann M . Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol. 2012; 139(1):49-56. DOI: 10.1007/s00432-012-1297-9. View

17.

Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E . uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. 2013; 121(7):392-7. DOI: 10.1002/cncy.21287. View

18.

Mengual L, Ribal M, Lozano J, Ingelmo-Torres M, Burset M, Fernandez P . Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models. J Urol. 2013; 191(1):261-9. DOI: 10.1016/j.juro.2013.06.083. View

19.

Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I . Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?. World J Urol. 2014; 33(9):1309-13. DOI: 10.1007/s00345-014-1452-9. View

20.

Schmitz-Drager B, Droller M, Lokeshwar V, Lotan Y, Hudson M, van Rhijn B . Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2014; 94(1):1-24. DOI: 10.1159/000369357. View